SCHEMBL7122665

SCHEMBL7122665

C=CCN(O)c1cccc2c1C(=O)c1ccccc1C2=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
PABPC1 P11940 3/20 0.54
L3MBTL1 Q9Y468 5/20 0.53
MAPT P10636 5/20 0.53
ALDH1A1 P00352 5/20 0.53
MAPK1 P28482 4/20 0.53
TDP1 Q9NUW8 3/20 0.53
EGFR P00533 2/20 0.53
NSD2 O96028 1/20 0.53
LMNA P02545 1/20 0.53
KDM4E B2RXH2 2/20 0.47
ADORA2A P29274 1/20 0.41
RAB9A P51151 3/20 0.41
MAOA P21397 2/20 0.41
PTK2B Q14289 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ELANE P08246 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL728510 0.84 MEN1 (0.60) MEN1KMT2APABPC1L3MBTL1MAPT
SCHEMBL7129845 0.82 L3MBTL1 (0.53) MEN1KMT2APABPC1L3MBTL1MAPT
SCHEMBL4732623 0.80 MAPT (0.62) MEN1KMT2APABPC1L3MBTL1MAPT
SCHEMBL8855198 0.78 MEN1 (0.56) MEN1KMT2APABPC1L3MBTL1MAPT
SCHEMBL11577264 0.77 PABPC1 (0.49) MEN1KMT2APABPC1L3MBTL1MAPT
SCHEMBL9765744 0.77 MAPT (0.58) MEN1KMT2APABPC1L3MBTL1MAPT
SCHEMBL9393651 0.77 MAPT (0.67) MEN1KMT2APABPC1L3MBTL1MAPT
SCHEMBL27680308 0.75 MAPT (0.46) MEN1KMT2APABPC1L3MBTL1MAPT
SCHEMBL5696019 0.74 MAPT (0.54) MEN1KMT2APABPC1L3MBTL1MAPT
SCHEMBL11316550 0.74 MAPT (0.62) MEN1KMT2APABPC1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4230619-A None JP disclosed
US-20030130272-A1 Anthracene derivatives as anti-cancer agents BTG INTERNATIONAL LIMITED (GB) 2003-07-10 US disclosed
EP-1244624-A1 ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS BTG INTERNATIONAL LIMITED (GB) 2002-10-02 EP disclosed
WO-2001044190-A1 ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS BTG INTERNATIONAL LIMITED (GB) 2001-06-21 WO disclosed
JP-H04230619-A HAIR DYEING COMPOSITION CONTAINING ANTHRAQUINONE COMPOUND L'OREAL SA 1992-08-19 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130272-A1 Anthracene derivatives as anti-cancer agents TOP2B, TOP1, TOP2A MEN1 3649/4885KMT2A 3784/4885PABPC1 2753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.